For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, President and Representative Director
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshiaki Sai, General Manager,
Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com/

Daiichi Sankyo Establishes New Subsidiary in China

Tokyo, Japan (November 18, 2011)- Daiichi Sankyo Company Limited (hereafter, Daiichi Sankyo) today announced the establishment of its 100 percent owned China subsidiary DAIICHI SANKYO (CHINA) HOLDINGS CO., LTD. (hereafter, Daiichi Sankyo China) in Shanghai.

 

Daiichi Sankyo China will manage the operations of DAIICHI SANKYO PHARMACEUTICAL (BEIJING) CO., LTD. and DAIICHI SANKYO PHARMACEUTICAL (SHANGHAI) CO., LTD., promoting quick decision making and strategic investment to ensure further growth and greater presence for the Daiichi Sankyo Group in China.

 

Profile of the new company 

1. Name: DAIICHI SANKYO (CHINA) HOLDINGS CO., LTD.

2. Date of establishment: November 8, 2011

3. Location: Shanghai, China

4. Representative: Takeshi Shigihara (Chairman of The Board, President)

5. Business: Management of Chinese subsidiary business and investment

6. Capital: USD $30 million

 

 

For reference:

Overview of DAIICHI SANKYO PHARMACEUTICAL (BEIJING) CO., LTD.

1. Date of establishment: May, 1998

2. Location: Beijing, China

3. Representative: Takeshi Shigihara (Chairman of The Board, President)

4. Business: Development, manufacturing and sale of pharmaceuticals

5. Capital: USD $63.8 million

6. Sales: JPY 4.2 billion in FY2010

7. Employees: 494 (Approximately 180 sales representatives) (current as of September 30, 2011)

8. Main products: Synthetic antibacterial agent Cravit®

 

Overview of DAIICHI SANKYO PHARMACEUTICAL (SHANGHAI) CO., LTD.

1. Date of establishment: November, 1999

2. Location: Shanghai, China

3. Representative: Takeshi Shigihara (Chairman Of The Board) and Yoho Tsutsumi (Member of Board & President)

4. Business: Research, Development, manufacturing and sale of pharmaceuticals

5. Capital: USD $53 million

6. Sales: JPY 6.6 billion in FY2010

7.Employees: 691 (Approximately 330 sales representatives) (current as of September 30, 2011)

8. Main products: Antihypertensive agent Olmetec®, hypercholesterolemia drug Mevalotin®, analgesic and anti-inflammatory drug Loxonin®, cough suppressant Asmeton®, antibiotic agent Cefmetazon®, oral antibacterial agent Carbenin®